Quantum BioPharma Ltd. is trading 10.6% down at $3.62 as selling pressure intensifies following an FDA clinical hold on its lead multiple sclerosis candidate, Lucid-MS.
- Shares have plummeted from $6.86 on May 29, 2026, marking multiple consecutive daily declines as regulatory uncertainty weighs on the small-cap biotech.
- Fragile investor sentiment is being further exacerbated by broader downward pressure across U.S. equity markets.